2020.04.28 23:25
"A study of Gilead’s remdesivir drug conducted by the National Institute of Allergy and Infectious Diseases met its primary endpoint, the drugmaker said, lifting expectations for a potential coronavirus treatment. Gilead also released the results of its own study, which showed improvement in patients taking remdesivir to treat the virus. Gilead shares jumped 9.3 after a brief halt. "
2020.04.29 00:12
2020.04.29 02:50
Again, my concern is not only the antiviral agents but also the critical issue of the vaccine! No one seems to know how much the vaccine can help the immune system to generate the antibody enough to fight off this peculiar Wuhan virus in hybrid condition of common Corona virus combined with the HIV virus and how long the antibody would remain effective. Indeed I recall my transplant surgery fellowship days at MCV in Richmond to have spent most of the time to figure out the role of ALG (antilymphocytic globulin) as an immunosuppressant so that I become more skeptical on this vaccine issue involved to such hybrid virus!
BB Lee
2020.04.29 03:14
2020.04.29 04:10
Hope for the best, doc!
At least it sounds better than Clorox or Quinine, Idiot tried hard to sell!
BB Lee
2020.04.29 04:34
Thank you, Professor, for your comment.
Top news |
Getty Images |
|
2020.04.29 04:56
White House health advisor Dr. Anthony Fauci said that data from a coronavirus drug trial testing
Gilead Sciences’ antiviral drug remdesivir showed “quite good news.”
Speaking to reporters from the White House, Fauci said he was told data from the trial showed
“clear cut positive effect in diminishing time to recover.”
U.S. health officials are expected to release the full results of a drug trial conducted by the National Institute
of Allergy and Infectious Diseases later Wednesday. Gilead Sciences announced earlier in the day
that the study had met its primary endpoint, but did not provide further details. —Berkeley Lovelace Jr.
2020.04.29 06:10
NIH Trial data discussed below.
FDA approved the use of Remdesivir on patients with COVID19 today on an emergency basis.
It just shows how desperate we humans are in this war.
2020.04.29 22:30
https://news.joins.com/article/23766888?cloc=joongang-home-newslistleft
[출처: 중앙일보] 렘데시비르, 코로나 잡는 신약될까…같은 날 정반대 임상결과
No. | Subject | Date | Author | Last Update | Views |
---|---|---|---|---|---|
Notice | How to write your comments onto a webpage [2] | 2016.07.06 | 운영자 | 2016.11.20 | 18193 |
Notice | How to Upload Pictures in webpages | 2016.07.06 | 운영자 | 2018.10.19 | 32348 |
Notice | How to use Rich Text Editor [3] | 2016.06.28 | 운영자 | 2018.10.19 | 5924 |
Notice | How to Write a Webpage | 2016.06.28 | 운영자 | 2020.12.23 | 43840 |
8843 | 연꽃 따는 노래 | 2024.05.01 | 정관호*63 | 2024.05.01 | 13 |
8842 | 훈민정음의 비밀 [5] | 2024.04.25 | 운영자 | 2024.05.01 | 61 |
8841 | 부산정치파동과 미국의 이승만 제거계획 | 2024.04.25 | 온기철*71 | 2024.04.25 | 23 |
8840 | 코너킥으로 웃었다... 황선홍호, 일본 제압하고 8강으로 [5] | 2024.04.22 | 황규정*65 | 2024.04.25 | 30 |
8839 | [시조]懷古歌: 회고가 [1] | 2024.04.21 | 정관호*63 | 2024.04.21 | 12 |
8838 | 부산형무소 살해사건 | 2024.04.20 | 온기철*71 | 2024.04.20 | 18 |
8837 | 육군 방첩대. 미군 CIC, 그리고 김창룡 | 2024.04.17 | 온기철*71 | 2024.04.25 | 20 |
8836 | 김구의 일생과 암살의 원인 | 2024.04.14 | 온기철*71 | 2024.04.25 | 18 |
8835 | OPERA MIGNON: Connais tu le pays [1] | 2024.04.12 | 정관호*63 | 2024.04.12 | 25 |
8834 | “쏘니,너와 함께 뛴건 행운!”, 400경기 감동 축하영상 [5] | 2024.04.06 | 황규정*65 | 2024.04.22 | 34 |
8833 | 길에서 만난 한식 [1] | 2024.04.03 | 정관호*63 | 2024.04.09 | 33 |
8832 | 돌아오는 기러기 [1] | 2024.03.27 | 정관호*63 | 2024.04.18 | 46 |
8831 | 이강인-손흥민 ‘골 합작’ 한국, 태국 3-0 완승…월드컵 최종 예선 진출 성큼 [2] | 2024.03.26 | 황규정*65 | 2024.03.27 | 43 |
8830 | 1945년 8월 15일 오후 강릉 홍제정 안마을에서 [2] | 2024.03.19 | 정관호*63 | 2024.03.24 | 76 |
8829 | 이승만은 왜 김구를 제거 했을까? [1] | 2024.03.17 | 온기철*71 | 2024.03.18 | 52 |
8828 | My Grandson [1] | 2024.03.15 | 노영일*68 | 2024.03.18 | 107 |
8827 | 蜀相(촉상): 촉한 승상 제갈량 [1] | 2024.03.15 | 정관호*63 | 2024.04.12 | 59 |
8826 | 1945년 8월15일에는 서울에 아무일도 없었다. [1] | 2024.03.13 | 온기철*71 | 2024.03.14 | 53 |
8825 | 왕소군 고향에서 [1] | 2024.03.08 | 정관호*63 | 2024.03.20 | 58 |
8824 | 정약용; 늙어가면 친구가 점점 없어진다. [5] | 2024.03.06 | 온기철*71 | 2024.03.08 | 97 |
Gilead says shorter remdesivir regimen is effective
and drug met main goal in government study
Published: April 29, 2020 at 8:57 a.m. ETBy
Gilead Sciences Inc. GILD, +3.02% on Wednesday morning announced data from two clinical trials testing its experimental drug remdesivir in severely ill COVID-19 patients. The drugmaker's stock was halted in premarket trading on Wednesday in advance of company disclosures about remdesivir's performance in the studies. Gilead said an open-label Phase 3 trial testing the therapy in severely ill patients found that those taking a 5-day or 10-day course of treatment led to similar results. At least 52% of participants taking either dosing regimen were discharged from the hospital after 14 days of treatment, and at least 53% of those patients were reported as reaching "clinical recovery." "Multiple concurrent studies are helping inform whether remdesivir is a safe and effective treatment for COVID-19," Gilead chief medical officer Merdad Parsey said in a statement. "The study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir." Minutes before this topline data was released, Gilead also said that a government-run clinical trial evaluating remdesivir in severely ill COVID-19 patients met the study's primary endpoint. That study is being conducted by the National Institute of Allergy and Infectious Diseases, which is expected to provide additional information about that trial, Gilead said. Gilead's stock has gained 21.0% year-to-date, while the S&P 500 SPX, 1.81% is down 11.3%.